Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Paratek Pharmaceuticals Inc.

www.paratekpharm.com

Latest From Paratek Pharmaceuticals Inc.

Finance Watch: Investment In Novel Antibacterials Gets A New Boost With Qpex Launch

Repeat antibiotic entrepreneurs raised $33m to launch Qpex with assets from The Medicines Co. Also, Taiho increases VC fund to $300m and TP Therapeutics raises $80m.

Financing StartUps and SMEs

QIDP Program Heads Into Uncomplicated Territory: Iterum, Paratek Eye uUTI Indications

Iterum’ssulopenem is first QIDP candidate to enter Phase III for uncomplicated urinary tract infection; Paratek’sNuzyra could be next.

Review Pathway Clinical Trials

EU Accelerated Assessment Tracker: First Filing From Bluebird And Daiichi Keeping Mum

As the European Medicines Agency gets on with its fast-track review of bluebird bio's LentiGlobin gene therapy, the Pink Sheet takes a look at the year so far in the area of accelerated assessment. Daiichi Sankyo is keeping us guessing on whether its investigational new product, quizartinib, will also be fast-tracked once filed.

Review Pathway Europe

Keeping Track: US FDA Approves Novel Tetracyclines Nuzyra And Seysara; Hemlibra Indication Expands

The latest drug development news and highlights from our US FDA Performance Tracker.
Approvals Drug Review
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Transcept Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Paratek Pharmaceuticals Inc.
  • Senior Management
  • Evan Loh, MD, CEO
    Douglas P Pagan, CFO
    Adam Woodrow, Pres. & Chief Commercial Officer
  • Contact Info
  • Paratek Pharmaceuticals Inc.
    Phone: (617) 807-6600
    75 Park Plaza, 4th Fl.
    Boston, MA 02116
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register